AI patient-finding is the most transformative capability in a launch. It's also the most oversold, and the difference between the two is everything. The short version: In rare and specialty disease, surfacing miscoded patients isn't incremental. It's the launch. The same pitch aimed at primary care targets a bottleneck that was never the constraint. Either way, a patient the model surfaces still needs a human and a system ready to act. Start with where it's real. In rare and

"AI predicts launch success" is the line everyone is selling right now. It also happens to be pointed at the easier half of the problem. The short version: Predictive launch tracking is real, and the people running pharma's biggest AI programs are still careful about the claim. Prediction works when a problem holds still, and a launch doesn't. The ROI lives in response time, not in the forecast, so buy the sensor and build the reflexes. IQVIA describes active launch tracking